01
Why it is on repair menus
Anti-inflammatory signaling is the pitch. Evidence is still largely preclinical. Availability is still no.
- ·Barrier and inflammation models
- ·Not a diagnosis of colitis or eczema
- ·Not orderable
RE GEN RX · peptides / KPV
Under FDA review
KPV
An anti-inflammatory tripeptide PCAC recommended — not orderable until FDA lists it.
Oswego, Illinois · 74 W. Washington St · serving the Fox Valley. A licensed Illinois clinician still decides. Compounded medications are not FDA-approved.
Legal status reviewed July 2026 · Gut, skin, recovery comfort
What is KPV?
The molecule, in plain language.
KPV is a tripeptide fragment of alpha-MSH studied for anti-inflammatory and barrier-related research, including gut and skin models. PCAC recommended it for the 503A bulks list in July 2026. RE GEN will not compound it on a vote.
How people usually take it. Not orderable.
What people are actually trying to solve.
Interest is not a result. We keep the research language and skip the miracle.
02
Blends
Klow Blend stacks GHK-Cu / KPV / BPC-157 / TB-500. Three of those four are not orderable. The blend is not orderable.
- ·Request topical GHK-Cu alone
- ·See Klow page
- ·No partial gray-market stack
03
After FDA, maybe
If listing happens, we will add KPV with its basis. Until then, this page stays a no.
- ·Confirmation, not a vote
- ·We will update copy
- ·Start a visit for carried options
What the evidence actually is — and what it isn’t.
A note on honesty: we will tell you what the literature supports and what it does not. Animal data is not a human guarantee. Anecdotes are not trials.
Animal research
KPV has preclinical anti-inflammatory and barrier literature.
- ·Gut and skin models
- ·Not listing yet
- ·Not orderable
Human research
Human data are limited. PCAC recommendation is not approval.
- ·Not orderable
- ·No inflammation-score promise
- ·Do not buy research KPV
Legal basis at RE GEN · July 2026
We will not compound this today.
PCAC recommended KPV for the 503A bulks list on July 23, 2026. Not orderable at RE GEN until FDA acts.
PCAC recommended listing is not a green light. Not orderable today.
Common questions
Peptide education for Illinois patients at RE GEN in Oswego — not a substitute for a visit.
What is KPV?
A tripeptide fragment of alpha-MSH studied for inflammation and barrier models. PCAC recommended listing in July 2026. Not orderable yet.
Is KPV FDA-approved?
KPV is not FDA-approved, and RE GEN does not have a lawful §503A pathway to request it as a compounded medication today. A committee vote is not approval.
Can I get KPV at RE GEN in Oswego?
You can start a visit to talk about your goal. We will not compound KPV today. We will show you what is carried instead — and we will say no rather than gray-market a vial.
Can you put it in a glow blend?
No. Blends that include KPV, BPC-157, or TB-500 are not orderable.
Do you promise results?
No. Educational pages explain why people ask and what the research landscape looks like. Individual response varies. Compounded medications are not FDA-approved, and a request is not a guaranteed prescription.
Related on this menu
BPC-157 (injectable)
Most-asked repair peptide
Learn more →
BPC-157 (oral)
Needle-free
Learn more →
TB-500
Often paired with BPC-157
Learn more →
GHK-Cu
Topical solution · 0.25%
Learn more →
Cardiogen
Clinician-matched only
Learn more →
Wolverine Blend
BPC-157 / TB-500
Learn more →
Glow Blend
GHK-Cu / BPC-157 / TB-500
Learn more →
Klow Blend
GHK-Cu / KPV / BPC-157 / TB-500
Learn more →
Illinois practice · licensed 503A compounding
A committee vote is not a green light. We add a peptide when FDA does.
Hello Gorgeous PC · 74 W. Washington St, Oswego, IL
RE GEN desk 630-636-6193
Start a visit, a licensed Illinois clinician reviews, then you pay the invoice. If they don't prescribe, we refund.